MX2013004906A - Nuevos inhibidores especificos de la proteasa ns3 de hcv. - Google Patents

Nuevos inhibidores especificos de la proteasa ns3 de hcv.

Info

Publication number
MX2013004906A
MX2013004906A MX2013004906A MX2013004906A MX2013004906A MX 2013004906 A MX2013004906 A MX 2013004906A MX 2013004906 A MX2013004906 A MX 2013004906A MX 2013004906 A MX2013004906 A MX 2013004906A MX 2013004906 A MX2013004906 A MX 2013004906A
Authority
MX
Mexico
Prior art keywords
protease inhibitors
novel specific
specific hcv
hcv
novel
Prior art date
Application number
MX2013004906A
Other languages
English (en)
Spanish (es)
Inventor
Philippe Halfon
Jerome Courcambeck
Mourad Bouzidi
Steven J Coats
Richard Anthony Whitaker
Original Assignee
Genoscience Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genoscience Pharma filed Critical Genoscience Pharma
Publication of MX2013004906A publication Critical patent/MX2013004906A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
MX2013004906A 2010-11-01 2011-10-28 Nuevos inhibidores especificos de la proteasa ns3 de hcv. MX2013004906A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40898910P 2010-11-01 2010-11-01
PCT/US2011/058404 WO2012061248A2 (en) 2010-11-01 2011-10-28 Novel specific hcv ns3 protease inhibitors

Publications (1)

Publication Number Publication Date
MX2013004906A true MX2013004906A (es) 2013-12-06

Family

ID=46025037

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004906A MX2013004906A (es) 2010-11-01 2011-10-28 Nuevos inhibidores especificos de la proteasa ns3 de hcv.

Country Status (10)

Country Link
US (1) US8729014B2 (OSRAM)
EP (1) EP2635570B1 (OSRAM)
JP (1) JP5828903B2 (OSRAM)
CN (1) CN103328466B (OSRAM)
AU (1) AU2011323658A1 (OSRAM)
BR (1) BR112013010836A2 (OSRAM)
CA (1) CA2815855C (OSRAM)
IL (1) IL225908A0 (OSRAM)
MX (1) MX2013004906A (OSRAM)
WO (1) WO2012061248A2 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012033022A2 (pt) 2010-06-24 2016-12-20 Genosciense Pharma Sas tratamento de vírus de hepatite c relacionado a doenças utilizando hidroxicloroquina ou uma combinação de hidroxicloroquina e um agente antiviral
EP2635570B1 (en) 2010-11-01 2017-12-13 RFS Pharma, LLC. Novel specific hcv ns3 protease inhibitors
WO2012176149A1 (en) 2011-06-23 2012-12-27 Panmed Ltd. Treatment of hepatitis c virus
CN104039774A (zh) 2012-01-12 2014-09-10 Rfs制药公司 Hcv ns3蛋白酶抑制剂
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
SG11201507223TA (en) 2013-03-15 2015-10-29 Gilead Sciences Inc Macrocyclic and bicyclic inhibitors of hepatitis c virus
US9926295B2 (en) * 2014-04-15 2018-03-27 Cocrystal Pharma, Inc. Potent and selective inhibitors of hepatitis C virus
CN105315261A (zh) * 2014-08-04 2016-02-10 正大天晴药业集团股份有限公司 Hcv ns3蛋白酶抑制剂的钠盐

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000536A1 (en) 1993-06-22 1995-01-05 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds
CZ298749B6 (cs) 1996-10-18 2008-01-16 Vertex Pharmaceuticals Incorporated Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
JP4806154B2 (ja) 2000-04-03 2011-11-02 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼのインヒビター
CA2462200A1 (en) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2004032827A2 (en) 2002-05-20 2004-04-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
BRPI0412502A (pt) 2003-07-10 2006-09-19 Achillion Pharmaceuticals Inc derivados de ariltiouréia substituìda úteis como inibidores de replicação viral
KR20120090077A (ko) 2004-01-30 2012-08-16 얀센 알 앤드 디 아일랜드 Ｈｃｖ ｎｓ?３ 세린 프로테아제 저해제
CN1984922A (zh) 2004-05-20 2007-06-20 先灵公司 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的取代脯氨酸
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2006111906A2 (en) 2005-04-19 2006-10-26 Philips Intellectual Property & Standards Gmbh Illumination system comprising a red-emitting ceramic luminescence converter
TWI387603B (zh) 2005-07-20 2013-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
KR20080036598A (ko) 2005-08-01 2008-04-28 머크 앤드 캄파니 인코포레이티드 Ｈｃｖ ｎｓ３ 프로테아제 억제제로서의 마크로사이클릭펩티드
JP2009524681A (ja) 2006-01-27 2009-07-02 フェノミックス コーポレーション Ｃ型肝炎ウイルスセリンプロテアーゼインヒビターおよびそのための使用
CN101495457A (zh) * 2006-07-05 2009-07-29 因特蒙公司 C型肝炎病毒复制的新颖抑制剂
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
US7635683B2 (en) 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
CN101553170B (zh) 2006-11-24 2011-11-09 株式会社岛津制作所 X射线透视摄影装置
US20080287449A1 (en) 2007-04-26 2008-11-20 Deqiang Niu Aza-tripeptide hepatitis c serine protease inhibitors
CA2708150A1 (en) * 2007-12-05 2009-06-18 Enanta Pharmaceuticals, Inc. Fluorinated tripeptide hcv serine protease inhibitors
CA2710144A1 (en) * 2007-12-21 2009-07-02 Avila Therapeutics, Inc. Hcv protease inhibitors and uses thereof
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
KR20110005869A (ko) 2008-04-15 2011-01-19 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규한 마크로사이클릭 억제제
KR101781789B1 (ko) * 2010-01-27 2017-09-26 에이비 파르마 리미티드. C형 간염 바이러스 억제제로 사용되는 다환 헤테로사이클릭 화합물
EP2635570B1 (en) 2010-11-01 2017-12-13 RFS Pharma, LLC. Novel specific hcv ns3 protease inhibitors

Also Published As

Publication number Publication date
JP2013542955A (ja) 2013-11-28
CA2815855A1 (en) 2012-05-10
US8729014B2 (en) 2014-05-20
EP2635570A4 (en) 2014-04-16
WO2012061248A8 (en) 2013-08-01
CA2815855C (en) 2016-02-02
CN103328466B (zh) 2016-08-03
WO2012061248A3 (en) 2012-08-02
EP2635570A2 (en) 2013-09-11
US20120129765A1 (en) 2012-05-24
BR112013010836A2 (pt) 2019-09-24
JP5828903B2 (ja) 2015-12-09
EP2635570B1 (en) 2017-12-13
CN103328466A (zh) 2013-09-25
IL225908A0 (en) 2013-06-27
WO2012061248A2 (en) 2012-05-10
AU2011323658A1 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
WO2013106689A8 (en) Hcv ns3 protease inhibitors
TN2012000264A1 (en) Hepatitis c virus inhibitors
TN2012000214A1 (en) Hepatitis c virus inhibitors
MX2011008045A (es) Inhibidores del virus de la hepatitis c.
MY152971A (en) Hepatitis c virus inhibitors
MX337936B (es) Compuestos inhibidores del virus de la hepatitis c.
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
MX2013001579A (es) Inhibidores del virus de la hepatitis c
MY153766A (en) Derivatised proline containing peptide organic compounds as protease inhibitors
MX2010008531A (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
SG179566A1 (en) Hcv protease inhibitors
EA201071315A1 (ru) Ингибиторы протеазы вируса гепатита с
PH12013501543A1 (en) Hepatitis c virus inhibitors
MX2010008749A (es) Inhibidores del virus de la hepatitis c.
ES2572329A2 (es) Combinacion de al menos dos agentes antivirales de accion directa y ribavirina pero no interferon, para uso en el tratamientodel vhc
WO2012072713A3 (en) Lysine demethylase inhibitors such as cyclylcyclopropanamine derivatives for use in the treatment of diseases and disorders associated with flaviviridae
WO2012083048A3 (en) Anti-viral compounds
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
MX2013002927A (es) Inhibidores del virus de la hepatitis c.
WO2012083053A3 (en) Anti-viral compounds
IN2014CN03113A (OSRAM)
WO2011150190A3 (en) Hcv inhibitor compounds and methods of use thereof
WO2012061248A3 (en) Novel specific hcv ns3 protease inhibitors
PL2209789T3 (pl) Skondensowane z cyklopropylem indolobenzoazepinowe inhibitory NS5B HCV

Legal Events

Date Code Title Description
FG Grant or registration